# Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement Canonical URL: https://biopharmsignal.com/news/XCUR/exicure-announces-receipt-of-nasdaq-notice-regarding-minimum-stockholders-equity-7d2e1517 Ticker: XCUR Company: Exicure Source: Exicure Published: 2026-06-10 20:01 EST ## Summary Exicure received a Nasdaq notice regarding non-compliance with the minimum stockholders’ equity requirement and plans to regain compliance.... ## Article Body Exicure, Inc. (Nasdaq: XCUR) (the “Company”) today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on June 5, 2026 indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders’ equity. As reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, the Company reported stockholders’ equity of approximately $2.1 million. Nasdaq also determined that the Company does not currently satisfy the alternative continued listing standards relating to market value of listed securities or net income from continuing operations. The Company believes that its financial position and stockholders’ equity were impacted in part by executive separation-related expenses and obligations under certain long-term consulting arrangements entered into prior to the current management team's appointment. Under the current management team, the Company has implemented significant cost-reduction and restructuring initiatives, including the termination of substantially all non-essential legacy consulting arrangements . The notification has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market. Under Nasdaq rules, the Company has 45 calendar days, or until July 20, 2026, to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, Nasdaq may grant an extension of up to 180 calendar days from the date of the notice to regain compliance. The Company intends to submit a compliance plan within the prescribed timeframe and is evaluating various alternatives to regain compliance with the applicable listing requirements. About Exicure, Inc. Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. In January 2025, it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases. The Company’s lead program in development is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. For more information, visit www.exicuretx.com . Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the Company’s plans to regain compliance with Nasdaq listing requirements. Actual results may differ materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation to update any forward-looking statements except as required by law. Media Contact: Exicure, Inc. pr@exicuretx.com ## Recent Company News - 2026-06-30 12:40 EST — [Exicure Announces Board and Committee Changes](https://biopharmsignal.com/news/XCUR/exicure-announces-board-and-committee-changes-3e7d491d) — Source: Exicure - 2026-06-10 20:01 EST — [Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement](https://biopharmsignal.com/news/XCUR/exicure-announces-receipt-of-nasdaq-notice-regarding-minimum-stockholders-equity-7d2e1517) — Source: Exicure - 2026-06-01 20:00 EST — [Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q](https://biopharmsignal.com/news/XCUR/exicure-announces-receipt-of-nasdaq-delinquency-notice-and-filing-of-form-10-q-47e8448d) — Source: Exicure - 2026-04-22 23:54 EST — [Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)](https://biopharmsignal.com/news/XCUR/exicure-announces-co-development-agreement-with-adbiotech-for-burixafor-gpc-100-eafcfb43) — Source: Exicure - 2026-04-02 20:01 EST — [Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions](https://biopharmsignal.com/news/XCUR/summary-notice-of-pendency-and-proposed-settlement-of-stockholder-derivative-act-c6597e3a) — Source: Exicure ## Related News - 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a) - 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce) - 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9) - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)